Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of hepatitis C with new fixed dose combinations.

Expert opinion on pharmacotherapy - 1 Aug 2017

Soriano Vincent, Fernandez-Montero José V, de Mendoza Carmen, Benitez-Gutierrez Laura, Peña José M, Arias Ana, Barreiro Pablo

Abstract excerpt

INTRODUCTION: The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepacivirus
Share to Hepatitis C
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Drug Combinations

Share to Medication Adherence

Source

Identifiers

PMID: 28644739
DOI: 10.1080/14656566.2017.1346609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of hepatitis C with new fixed dose combinations.PMID 28644739Read ↗

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.Semantic proximity Read ↗

Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

The current treatment of Hepatitis C.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

Pan‐genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high‐ and low‐income regionsSemantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Treatment of chronic HCV genotype 1 coinfection.Semantic proximity Read ↗

Novel therapies for hepatitis C - one pill fits all?Semantic proximity Read ↗

Regimens for the Hepatitis C Treatment-Naive Patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.